Skip to content

Exploration of neuroscience

ISSN 2834-5347

2 papers in the library · 4 citations · publishing 2024-2025

Papers

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?

Exploration of neuroscience August 7, 2025 Trevor R. Norman 2 citations

A single dose of psilocybin, given alongside intensive psychotherapy, produces a rapid and clinically significant decline in depressive symptoms in people with treatment resistant depression, with benefits mostly retained at 12 weeks or longer. Psilocybin was well tolerated; side effects were mostly mild to moderate and transient, including elevated blood pressure, fatigue, headache, nausea, and vertigo. Hallucinogen persisting perception disorder was occasionally reported, and there were few reports of suicidal ideation and behavior. Further controlled evaluations are necessary before routine use.

Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives

Exploration of neuroscience September 24, 2024 Bushra Yasin, Shivani Mehta, George Tewfik et al. 2 citations

Chronic neuropathic pain affects an estimated 1.5 billion people worldwide. Its mechanisms involve peripheral and central sensitization from repeated noxious stimuli, leading to physical and emotional pain. Traditional treatments like opioid and non-opioid analgesics often cause adverse effects, addiction, or suboptimal relief. Psychedelics such as psilocybin, LSD, mescaline, and MDMA are emerging as potential therapies. They alter pain perception by activating serotonin receptors, reducing inflammation, enhancing descending inhibition, and promoting neuroplasticity and synaptic remodeling. This review describes the mechanisms, pharmacology, clinical applications, and therapeutic potential of psychedelics for neuropathic pain.